Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Provention Bio"},{"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$4.0 million","newsHeadline":"CURE Pharmaceutical Closes $10 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cure Pharmaceutical"},{"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma FDA Acceptance of IND Application for ATRS-1902","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Antares Pharma"},{"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Biomea Fusion"}]

Biomea Fusion

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

Details:

Biomea plans to initiate a Phase I/II clinical trial of lead menin inhibitor BMF-219 in diabetes in the second half of 2022, subject to submission and clearance of an investigational new drug (IND) application.

Lead Product(s): BMF-219

Therapeutic Area: Endocrinology Product Name: BMF-219

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2022

ASK
US

Upload
your Pipeline Activity

Antares Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Antares Pharma FDA Acceptance of IND Application for ATRS-1902

Details:

The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.

Lead Product(s): Hydrocortisone

Therapeutic Area: Endocrinology Product Name: ATRS-1902

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2021

ASK
US

Upload
your Pipeline Activity

Cure Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CURE Pharmaceutical Closes $10 Million Financing

Details:

Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline

Lead Product(s): Sildenafil Citrate

Therapeutic Area: Endocrinology Product Name: CUREfilm Blue

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Axiom Capital Management

Deal Size: $10.0 million Upfront Cash: $4.0 million

Deal Type: Financing November 02, 2020

ASK
US

Upload
your Pipeline Activity

Provention Bio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine

Details:

Publication results demonstrates that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant animal models.

Lead Product(s): PRV-101

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY